189 related articles for article (PubMed ID: 19362977)
1. Fludarabine-based combination therapies for Waldenström's macroglobulinemia.
Tedeschi A; Alamos SM; Ricci F; Greco A; Morra E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):67-70. PubMed ID: 19362977
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine in Waldenstrom's macroglobulinemia.
Leblond V; Choquet S
Semin Oncol; 2003 Apr; 30(2):239-42. PubMed ID: 12720144
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine in Waldenstrom's macroglobulinemia.
Souchet-Compain L; Nguyen S; Choquet S; Leblond V
Expert Rev Hematol; 2013 Jun; 6(3):229-37. PubMed ID: 23782076
[TBL] [Abstract][Full Text] [Related]
4. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
Tam CS; Wolf MM; Westerman D; Januszewicz EH; Prince HM; Seymour JF
Clin Lymphoma Myeloma; 2005 Sep; 6(2):136-9. PubMed ID: 16231852
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia.
Tedeschi A; Ricci F; Goldaniga MC; Benevolo G; Varettoni M; Motta M; Pioltelli P; Gini G; Barate' C; Luraschi A; Vismara E; Frustaci AM; Nichelatti M; Vitolo U; Baldini L; Morra E
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):231-4. PubMed ID: 23490992
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine treatment in resistant Waldenstrom's macroglobulinemia.
Zinzani PL; Gherlinzoni F; Bendandi M; Zaccaria A; Aitini E; Salvucci M; Tura S
Eur J Haematol; 1995 Feb; 54(2):120-3. PubMed ID: 7698295
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine therapy in Waldenström's macroglobulinemia.
Dimopoulos MA; O'Brien S; Kantarjian H; Pierce S; Delasalle K; Barlogie B; Alexanian R; Keating MJ
Am J Med; 1993 Jul; 95(1):49-52. PubMed ID: 8328496
[TBL] [Abstract][Full Text] [Related]
9. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.
Keating MJ; McLaughlin P; Plunkett W; Robertson LE; O'Brien S; Gandhi V; Gregoire V; Yang L; Cabanillas F
Ann Oncol; 1994; 5 Suppl 2():79-83. PubMed ID: 8204523
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
Dimopoulos MA; O'Brien S; Kantarjian H; Estey EE; Keating MJ; Alexanian R
Leuk Lymphoma; 1993; 11 Suppl 2():105-8. PubMed ID: 7907250
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia.
Gavriatopoulou M; Kastritis E; Kyrtsonis MC; Vassilakopoulos TP; Roussou M; Fotiou D; Migkou M; Mpakiri M; Tasidou A; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2017 Jun; 58(6):1506-1508. PubMed ID: 27724158
[No Abstract] [Full Text] [Related]
13. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease.
Tedeschi A; Benevolo G; Varettoni M; Battista ML; Zinzani PL; Visco C; Meneghini V; Pioltelli P; Sacchi S; Ricci F; Nichelatti M; Zaja F; Lazzarino M; Vitolo U; Morra E
Cancer; 2012 Jan; 118(2):434-43. PubMed ID: 21732338
[TBL] [Abstract][Full Text] [Related]
14. Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia.
O'Brien S; Kantarjian H; Keating MJ
Ann Oncol; 1996; 7 Suppl 6():S27-33. PubMed ID: 9010576
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia.
Souchet L; Levy V; Ouzegdouh M; Tamburini J; Delmer A; Dupuis J; Le Gouill S; Pégourié-Bandelier B; Tournilhac O; Boubaya M; Vargaftig J; Choquet S; Leblond V;
Am J Hematol; 2016 Aug; 91(8):782-6. PubMed ID: 27135784
[TBL] [Abstract][Full Text] [Related]
16. Assessment of bone marrow response in Waldenström's macroglobulinemia.
Varghese AM; Rawstron AC; Ashcroft AJ; Moreton P; Owen RG
Clin Lymphoma Myeloma; 2009 Mar; 9(1):53-5. PubMed ID: 19362973
[TBL] [Abstract][Full Text] [Related]
17. Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine.
Shin SJ; Chun SH; Kim KO; Kim MK; Lee KH; Hyun MS; Cho HS
Jpn J Clin Oncol; 2005 Oct; 35(10):622-5. PubMed ID: 16172172
[TBL] [Abstract][Full Text] [Related]
18. Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.
Leblond V; Ben-Othman T; Deconinck E; Taksin AL; Harousseau JL; Delgado MA; Delmer A; Maloisel F; Mariette X; Morel P; Clauvel JP; Duboisset P; Entezam S; Hermine O; Merlet M; Yakoub-Agha I; Guibon O; Caspard H; Fort N
J Clin Oncol; 1998 Jun; 16(6):2060-4. PubMed ID: 9626204
[TBL] [Abstract][Full Text] [Related]
19. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
20. Alkylating agents for Waldenstrom's macroglobulinaemia.
Yang K; Tan J; Wu T
Cochrane Database Syst Rev; 2009 Jan; (1):CD006719. PubMed ID: 19160296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
